According to a new report from Intel Market Research, the global Buspirone Hydrochloride Tablets market was valued at USD 103 million in 2024 and is projected to reach USD 153 million by 2032, growing at a CAGR of 5.8% during the forecast period (2025–2032). This steady growth is driven by rising anxiety disorder prevalence and increasing adoption of non-benzodiazepine anxiolytics in clinical practice.
Buspirone Hydrochloride is a serotonin receptor agonist and dopamine receptor modulator prescribed for short-term management of anxiety disorders. Unlike traditional benzodiazepines, it demonstrates minimal sedation, addiction potential, or withdrawal symptoms, making it a preferred choice for generalized anxiety disorder (GAD) treatment. The drug is available in tablet form with standard dosages of 5mg, 10mg, and 15mg.
First approved by the FDA in 1986, buspirone has maintained its therapeutic relevance due to its unique mechanism of action and favorable safety profile. It is commercially available as generic medication worldwide, though some markets still carry branded versions under names like Buspar® (discontinued in the U.S. but available in select countries).
📥 Download FREE Sample Report:
Buspirone Hydrochloride Tablets Market - View in Detailed Research Report
1. Increasing Global Anxiety Disorder Burden
The World Health Organization estimates that anxiety disorders affect 301 million people worldwide, with growing recognition of mental health conditions post-pandemic. Buspirone's advantages over benzodiazepines—particularly its lower risk of dependency—position it as a sustainable therapeutic option for chronic anxiety management. Recent clinical guidelines from the American Psychiatric Association have reinforced its role as first-line pharmacotherapy for mild-to-moderate GAD.
2. Expanding Geriatric Patient Pool
With 16% of the global population projected to be over 65 by 2050 (United Nations data), geriatric-friendly anxiolytics are witnessing heightened demand. Buspirone's favorable pharmacokinetics in elderly patients—including reduced cognitive impairment risks compared to alternatives—make it particularly suitable for this demographic. Cardiology associations increasingly recommend it for anxiety management in patients with cardiovascular comorbidities.
While the outlook remains positive, several factors constrain market expansion:
Delayed onset of action: Requires 2-4 weeks for full therapeutic effect, limiting adoption in acute settings
Drug interaction concerns: Contraindicated with MAO inhibitors and impacted by CYP3A4 inducers/inhibitors
Patent expiry: Universal generic availability suppresses brand premium pricing opportunities
The market demonstrates distinct dynamics across dosage forms:
5mg tablets: Preferred for dose titration and elderly patients
10mg tablets: Most commonly prescribed maintenance dose
15mg tablets: Gaining traction for severe cases requiring BID/TID dosing
North America: Accounts for dominant market share due to high mental health awareness and established generic drug infrastructure
Europe: Shows steady growth with increasing emphasis on non-addictive anxiolytics in clinical guidelines
Asia-Pacific: Emerging as high-growth region with improving mental healthcare access and local generic production
By Type
5mg
10mg
15mg
By Application
Hospital
Clinic
Others
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
📘 Get Full Report Here:
Buspirone Hydrochloride Tablets Market - View in Detailed Research Report
The market features several established generic manufacturers, with key players including:
Teva Pharmaceuticals
PKU HealthCare
Jiangsu Nhwa Pharmaceutical
Beijing Huasu Pharmaceuticals
Market size projections through 2032
Dosage-form specific adoption trends
Regulatory landscape analysis
Pricing and reimbursement scenarios
Competitive benchmarking
📥 Download FREE Sample Report:
Buspirone Hydrochloride Tablets Market - View in Detailed Research Report
Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:
Real-time competitive benchmarking
Global clinical trial pipeline monitoring
Country-specific regulatory and pricing analysis
Over 500+ healthcare reports annually
Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.
🌐 Website: https://www.intelmarketresearch.com
📞 International: +1 (332) 2424 294
📞 Asia-Pacific: +91 9169164321
🔗 LinkedIn: Follow Us